-0.05 | -1.20%
| Price and Volume | |
|---|---|
| Recent Price | 4.15 |
| 52 Week High | 22.48 |
| 52 Week Low | 4.06 |
| Avg. Daily Vol. (Mil) | 0.78 |
| Beta (3 year) | 4.69 |
| Share Related Items | |
| Mkt Cap (Mil) | 138.61 |
| Shares Out (Mil) | 33.40 |
| Float (Mil) | 24.92 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.70 |
| Current Ratio | 3.70 |
| LT Debt/ Equity | 0.01 |
| Total Debt / Equity | 0.01 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 1.70 |
| Price/Book | 0.78 |
| Price/Cash Flow | -9.00 |
| Per Share Data | |
| Earnings | -0.58 |
| Sales | 2.44 |
| Book Value | 5.35 |
| Cash Flow | -0.46 |
| Business Summary | |
|---|---|
| A biopharmaceutical company, which is engaged in the design, discovery and development of NNR Therapeutics, a new class of drugs for the treatment of diseases and disorders of the central nervous system. | |
| General Information | |
| 200 East 1st Street
Suite 300 Winston-Salem, NC 27101-4165 |
|
| www.targacept.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 142 | |
| CEO: Dr. J. Donald deBethizy, | |
| Short Interest | |
| Current Month (Mil) | 3.99 |
| Previous Month (Mil) | 3.78 |
| Short Interest Ratio (Days) | 8.40 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -8.20 |
| Return on Investments | -10.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | -23.00 |
| Profit Margin | -23.10 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,419.86 | 1,313.32 | 2,837.36 | 16.25 |
Oil *
103.00
|
|
DOWN
160.83 |
DOWN
19.10 |
DOWN
33.63 |
DOWN
1.06 |
10 Yr
1.62%
SPDR Gold
151.91
|
|
-1.28%
|
-1.43%
|
-1.17%
|
-6.12%
|
Data delayed 20 minutes |
Connect with TheStreet